Usalco and G2O Technologies Merge

Usalco, a portfolio company of investment firm H.I.G. Capital, has completed a merger with G2O Technologies, owned by private equity group Arsenal Capital Partners. The merger creates one of North America’s leading water treatment chemical companies with 27 sites across the Americas.

The combined entity will continue to be known as Usalco and Ken Gayer, CEO of Usalco prior to the merger, will lead the new company. It will offer a range of products, including aluminum and iron salts, organic polymers and specialty blended formulations.

“Our complementary products and broader geographic reach will allow us to offer an expanded set of solutions that help improve our customers’ water treatment processes and protect our water resources,” said Gayer.

Including G2O, Usalco has completed four strategic transactions since H.I.G. recapitalized the business in June 2020. The other transactions were AlChem Specialties and CalChem Specialties in December 2020 and Altivia’s water treatment business in September of this year.

G2O Technologies, headquartered in Phillipsburg, New Jersey, was formed in April 2020 through a merger of Gulbrandsen and GEO Specialty Chemicals water treatment divisions.

Author: Elaine Burridge, Freelance Journalist

USALCO, a portfolio company of investment firm H.I.G. Capital, has merged with...
USALCO, a portfolio company of investment firm H.I.G. Capital, has merged with G2O Technologies, owned by private equity group Arsenal Capital Partners. The merger creates one of North America’s leading water treatment chemical firms with 27 sites across the Americas. Photo by J K on Unsplash

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

most read